IC
NMRA icon

Ikarian Capital’s Neumora Therapeutics NMRA Stock Holding History

Ikarian Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Hold
1,278,408
– – 0.2% 87
2025
Q4 		$2.29M Buy
1,278,408
+1,265,910
+10,129% +$2.77M 0.18% 97
2025
Q3 		$22.7K Hold
12,498
– – ﹤0.01% 168
2025
Q2 		$9.16K Sell
12,498
-2,959
-19% -$2.24K ﹤0.01% 133
2025
Q1 		$15.5K Buy
+15,457
New +$26.5K ﹤0.01% 159

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Ikarian Capital's NMRA Position: Q1 2026 in Review

Ikarian Capital held its Neumora Therapeutics (NMRA) position steady in Q1 2026 at 1,278,408 shares worth $2.49M. The position accounts for 0.2% of the portfolio, ranked #87.

Ikarian Capital first reported a position in NMRA in Q1 2025 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Ikarian Capital held 1,278,408 shares of Neumora Therapeutics worth $2.49M as of Q1 2026.
  • Ikarian Capital left its Neumora Therapeutics share count unchanged in Q1 2026.
  • Neumora Therapeutics made up 0.2% of Ikarian Capital's portfolio in Q1 2026, its #87 holding.
  • Ikarian Capital first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.